Connect with us

Cannabis News

Medical Marijuana ‘Significantly’ Decreases Use Of Opioids By Chronic Pain Patients, New Study Finds

Published

on

A new study shows that marijuana pain can be an effective replacement for the treatment of pain management.

Murdoch University researchers and research centers in Perth Pain Management Center to investigate how people who have been treating people with chronic cancer cancer pain.

Research published in Pain Management on Monday, “Cannabinoid co-prescriptions may be able to reduce the consumption prescribed for the chronic consumption of the pain kingdom.”

To assess the relationship between cannabis and opioids, the researchers followed two patients in a year: they were already in pain in the pain clinic and a Cannabis co-patient and another 53 patients, without Marijuanik, in a clinic.

Basically, median patient was taking about 40 mg opioids a day. After a year, 15 mg Delta-9 thc and 15 mg CBD median dose of 15 mg of CBD, the team “significantly” has reduced 2.7 mg of opioid doses per day. After a year, the opioid was only taking a median 42.3 mg per day.

“The introduction of cannabinoids can create useful reductions of opioid consumer settings in the real world, with additional benefits for disability and insomnia,” Authors of study celurbill. “However, this treatment is only subjected by a sub-group of patients.”

In the Kannabis treatment regiment between the cohort, “the opioid consumption has significantly reduced in 6 to 12 months.”

“Physical activity and sleep also improved. These findings indicate that medicinal cannabis can help patients reduce their opioid activity and improve their physical activity and sleep.

The findings are also consistent with the body of scientific literature, exploring the association between the use of cannabis and opioids.

For example, a study published this year earlier found in drug and alcohol review, among drug users who experience chronic pain every day The use of cannabis was related to greater probability of leaving opioids-Species among men.

Also found a study posted last year Legalization of medical cannabis seemed to significantly reduce the monetary payments of opioids What specializes in pain, authors “declining that in terms of Marijuana doctor, proves that they are available as a replacement.

Last studies also showed the decline of operating operations, legalized by marijuana for adults in jurisdictions. This study found a “Coherent negative relationship between legalization and aggression” has more significant effects on the states that were legalized before the cannon In opium crisis. The authors computed the legalization of recreation marijuana “that 3.5 per person per person is linked to reduction.”

“Our discoveries suggest that you can help recreating access to leisure marijuana to deal with the opioid epidemic,” said the report. “Previous research represents that marijuana (especially doctors) can reduce the prescriptions of opioids, and that we find that overdose can also reduce deaths.”

Another newly published report according to the use of Opioid opioid after the state Marijuana doctor legalization The availability of the legal cannabis was found that both patients with chronic pain reduced the opioid use and helped reduce deaths exceeded by prescription. Overall, the results of the study indicated that “Cannabis has a key role to play in pain management and reduce the use of opioids,” he said.

Another study published in 2023, linked to medical marijuana Minor level of pain and reduced dependence on opioids and other prescription medications. And other February, another published by the American Medical Association (Mother), found chronic pains that received medical marijuana for more than a month viewed important reductions in prescribed opioids.

About Three chronic pain patients reported using cannabis As a treatment option, 2023 mothers published by a report. Most of that group said they used cannabis as another substitute for pain medicines, including opioids.

Other research published that year found that People buy CBD legally significantly reduced opioid prescription feesIt has less recipe for 6.6 and 8.1 percent.

About prescription drugs Medicaid analyzed a 2022 research paper, while he found the legalization of marijuana for adult use “Reduced relevant” prescription drug use To treat multiple conditions.

2023 Report Medical Marijuana Medical Legalization Related Medical Payments reducing doctors-You have other data activities when they use legal access to the prescription drugs that patients use cannabis as an alternative.

Researchers in another study published last year examined Oregon opioid prescription and mortality rates to find it Marijuana retail access by reducing the prescriptions of oversized opioidsAlthough they saw a decline in the decline of death related to opioids.

Last research also indicates that cannabis can be an effective replacement of heels in terms of pain management.

Report published in BMJ magazine, such as marijuana and opioids for chronic painless pain and Canavies found “can be similarly effective and may have fewer interruptions than opioids” Provide potentially comparable relief with a lower chance of harmful effects.

Published special studies found more than half patients with chronic musculoskeletal pain, which was more effective than other analgesic medications cannabis, and 40% reported Reducing the use of other anes in the use of marijuana.

Marijuana is possible with the help of readers. If you are based on journalism to defend cannabis, consider the commitment to Patreon every month.

(Tagstotranslate) highlighted

Continue Reading

Cannabis News

“UK medical cannabis is maturing”

Published

on

By

The UK cannabis market has grown steadily over the past five years, although not always in the way operators had hoped. New brands and imported products have driven much of the expansion, while domestic cultivation has slowed. Alexander Mountain has seen this from the inside long before most people in the industry knew it existed. “I’ve been waiting for this since 2009,” says the founder of growing consultancy Trichome Solutions.

Regulations, compliance, EU-GMP requirements, all of which have made getting a facility off the ground a multi-year exercise. “I’ve worked with organizations and seen firsthand that it takes three, four, even five years to get going,” says Alexander. “It’s a tough market to break into in the UK, which in itself slows down the overall maturation.” The last six months, however, have brought about a change. “There are now clear goals and programs for business. An almost militant approach to protocols. It’s starting to feel like the rest of the EU and Canada.”

© Trichome Solutions

Capitalization and cultivation
Early investment in cannabis in the UK came largely from private capital, and the gap between capitalization and cultivation know-how cost many operators dearly. Consultants were brought in to design and build the facilities, but rarely stayed to operate them. The result was a facility that had to be rebuilt almost as soon as it opened. “A lot of adjustments, changes in workflows, logistical expansion,” says Alexander. “This, of course, requires more capital. This delays profitability and, in some cases, leads to employee burnout.” The model he believes in is the owner-operator structure that has worked in markets such as the US, Canada and Thailand.

In terms of cultivation, genetic selection and post-harvest are where Alexander gives most of his attention. Seasonal changes in the UK favor indoor parameters where possible, although low-light greenhouses have worked for some operators with adequate supplementary lighting. Getting the right genetics for the specific market drives early success and patient retention. Post-harvest, however, he believes the sector is constantly underestimating. “I focus a lot on preserving the plant material and maintaining its chemical profile, particularly cannabinoids, terpenes and volatile sulfur,” he says. “Even simple things, like having enough space to dry properly, seem like common sense. But unless you’ve actually done it, you don’t always realize how important those details are to the quality of the final product.”

UK cannabis demand
Patient demand in the UK has been shaped by the equity market, and licensed operators are working to close this gap. The dynamics here are different from other markets. In Germany and Canada, THC content drives purchasing decisions. In the UK, Alexander is seeing more focus on taste, aromas and the overall experience. “With the amount of choices coming in through imports, people are finding their own strains and becoming more selective,” he says. Closing this gap, in his opinion, involves the farmers as much as the prescribers. “Patient education and support should come from doctors. Producers should teach them about their products. I think growers should invite prescribers more often.”

Over the next three to five years, Alexander expects reliance on imports to ease as domestic supply chains develop and the market stabilizes. He says that there will be operators who come out from the other side, specialized ones. R&D, heritage genetics, premium indoor and post-harvest optimization. “We are now working in the international cannabis industry,” he says. “With comparisons, going on a flight, there is no room for complacency. The operators who find their niche and really excel in it will be the ones who build a strong identity and remain competitive in the cannabis space.”

For more information:
Trichoma solutions
(email protected)
trichomesolutions.com
Linkedin
Instagram

Continue Reading

Cannabis News

DC Mayor Proposes To Let Medical Marijuana And Alcohol Companies Partner On THC Drinks

Published

on

By

The mayor of Washington DC is proposing medical marijuana companies partner with local breweries and distilleries to produce cannabis-infused and non-alcoholic beverages for sale in the nation’s capital.

Under the partnership envisioned by Mayor Muriel Bowser’s (D) Medical Cannabis Beverage Products Amendment Act of 2026, alcohol companies can apply for a medical cannabis production endorsement at a cost of $500 per year to manufacture cannabis beverages, and medical marijuana companies can apply for a $1,000 annual endorsement to import cannabinoids for production.

All beverages would have to be tested by a locally licensed laboratory, and there would be a six percent sales tax on beverages.

“This is an opportunity to support two local industries and keep businesses in DC,” Bowser said in a press release. “We have great local brewers and distillers in our city, we have a strong medical cannabis market, and this is a new opportunity for those two markets to collaborate and create a safe, smoke-free alternative for DC patients”

Breweries and distilleries would not be able to sell cannabis beverages directly to consumers, and the finished products would instead go to medical marijuana manufacturers for testing and distribution.

Sales would be limited to registered medical cannabis patients through dispensaries, and drinks could not be purchased at bars, restaurants, liquor stores and grocery stores.

“It makes sense for the District’s medical cannabis and alcohol manufacturing industries to collaborate to produce medicinal cannabis beverages,” said Fred Moosally, director of the Alcoholic Beverages and Cannabis Administration. he said. “Providing a legal way for our local breweries and distilleries to use their expertise in beverage production is the next step in reaching DC’s medical cannabis market and supporting our local business ecosystem.”

A press release from the mayor’s office said the proposal “works to solve the manufacturing challenges of the medical cannabis industry while providing additional revenue for DC’s local craft beverage producers.”

“Using the existing local bottling infrastructure, DC will expand smokeless therapeutic options for medical cannabis patients, provide additional revenue for the local industry and continue to grow the District’s economy,” he said.

The legislation is now before the District of Columbia Council for consideration.

Although Congress has consistently blocked DC’s legalization of recreational marijuana sales with a pilot approved each year, local officials have worked. expand access through the existing cannabis market for example, allowing residents and even visiting tourists to self-certify without the need for a medical recommendation.

Marihuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

We’re a small grow, which means we can control things very well

Published

on

By

At 5,000 square feet, Flora Arbor is about as small as a licensed cannabis grower can legally get. That’s not the problem the company is trying to solve. “We’re a very small breed, which means we can control things very well.” he says David Myrowitz, director of cultivation. “It also means that we have to be successful in every round.” Three flower cells, collected in three weeks. There is no such thing as a bad lot to disappear into a larger average. Every shift counts, and the operation is built around that reality.

It starts in the pump room
Reverse osmosis water is fed into holding tanks, nutrients are mixed by an Agrowtek fertigation machine, and the entire system runs from a GCX controller that monitors moisture sensors, dissolved solids, and soil temperature in every room. Canopy sensors feed directly into HVAC, which Flora Arbor runs on Cultiva units. “If you talk to any grower, any grower, they’ll tell you the number one thing for successful growing is having a good HVAC system,” says David. “There is somewhere that we don’t have expenses.”

© Flora Arbor

Genetics and cells
Mother plants are removed every three to six months, so cuttings are always taken from young stock. The clones move from the humidity domes to a humidity-controlled room, then to the vegetables, where a crop-correction protocol runs several irrigation streams per day to encourage growth. Moisture sensors in the grow bags track each drying cycle, and daily watering patterns are revised based on the goals of the grow system.

The flower rooms have a double-level system, with taller plants at the bottom, shorter ones at the top, grouped to keep microclimates outside and an even distribution of light. The second mesh is lowered as the plants develop to give each bud site its own square and keep airflow moving through the canopy.

In a recent route, rooms from different phases of the cycle were working at the same time. Hawaiian Rain has been crossed with permanent marker, disk chips, cereal milk. David pointed to the development of crystals in the Hawaiian Rain cross, the citrus resin charge of Disco Fries, the height management challenge of pushing a cultivar as high as possible without burning them in the lights. “We try to have a nice spread of genetics, a nice representative of each flavor profile and effect, to make sure everyone can get something they like,” he says.

Crossing the finish line
Post-harvest is managed at home, by hand. The product is sorted on the cutting table A-Bd, B-Bud and cutting table, strictly separated, the grade on the label means something. The tiered structure also serves a second purpose. “We think it’s really important to make sure quality flowers are available to people of all means, not just people who can afford the premium,” says David. The three-week harvest cycle is Flora Arbor’s main argument for the consumer. Small batches, constant rotation, nothing stored.

“Every time you get a bag, it’s going to be fresh, freshly picked grass,” says David. “It’s not something that’s been sitting in some MSO’s vault for six months because they’ve collected 2,000 pounds and can’t sell it.” The bet is that in a market where no one has solved the consistency complaint, being small enough to catch all the cattle is more valuable than the economies of scale you allow to get there.

For more information:
Flora Arbor
1300 Abbott Dr, Elgin, IL 60123
847-504-8450
(email protected)
floraarbor.com

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media